explore -WSS

explore

author：fashion 2025-10-02 17:27:05 - browse：36618

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： An outdated Medicare rule harms dementia patients with anxiety

knowledge

WSS

How CO2 helps viruses stay alive longer in the air

ASCO Takeaways: Winners, snoozers, and the art of cancer care

What Kate Middleton's cancer revelation might teach the world

6 surprising facts about sugar

'Patient friction coefficient' can gauge a clinical trial's patient burden

Mirador, a new biotech startup, launches with $400 million

hotspot

explore

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Sutter Health’s antitrust win overturned by appeals court

What does generative AI mean for health care? We asked experts

With Wegovy coverage, Medicare patients may face high costs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Erich Jarvis studies song birds to learn about human stuttering

Medical leaders decry Supreme Court decision on affirmative action

How CO2 helps viruses stay alive longer in the air

Medical records are filled with copy

Medicare Advantage's lean provider networks lead CMS complaints

hotspot

What Kate Middleton's cancer revelation might teach the world

FTC loses bid to block Novant's North Carolina hospital merger

Asbestos ban is immediate, but health effects will linger for decades

CMS got Medicare Advantage quality rating wrong, judge rules

BD to buy Edwards patient monitoring unit for $4.2 billion

Testing GLP

knowledge

knowledge

focus

hotspot